BioPharma Dive December 10, 2024
Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, answers remained elusive on Pfizer’s abrupt withdrawal of Oxbryta.
The American Society of Hematology’s annual meeting continued Monday with important presentations and discussions on the latest blood disease research, several of which we’ve summarized here.
Sequencing BTK inhibitors in leukemia
In the years since the approval of Imbruvica for chronic lymphocytic leukemia a decade ago, it and other so-called BTK inhibitors have become mainstay treatments for the slow-growing blood cancer. Their adoption has given physicians new options to control the disease’s progression, but also new questions around how they might combine and sequence the therapies.
This year’s ASH meeting could give doctors...
Today's Sponsors
Today's Sponsor